Immunex Corp. and Wyeth’s pharmaceuticals unit said Enbrel was effective in treating moderate to severe plaque psoriasis, according to a Phase II study.
Enbrel, a fully human soluble receptor, has already demonstrated efficacy in treating patients with moderately to severely active rheumatoid arthritis.
Beyond Cash Donations: How New Forms of Giving Are Transforming Not-for-Profit Accounting
Evolving Funding Landscape for Not-for-Profits Not-for-profit organizations are being asked to do more with less,…
Learn More
In a press release Wednesday, Immunex said 53% of psoriasis patients treated with Enbrel were clear or almost clear of skin lesions at 6 months, compared to 5% of patients treated with placebo.
The companies also began a second, global Phase III pivotal study assessing the efficacy and tolerability of Enbrel to treat moderate to severe plaque psoriasis.
